Indivior, GB00BYZ0C031

Indivior stock heads into the open after a 0.77 percent drop

Published on 09/24/2026 at 05:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 23, 2026, Indivior stock stood at USD 35.91 on Nasdaq, while the Nasdaq Composite fell 1.13 percent. A USD 8.13 special dividend remains tied to the planned merger.

Moderne Pharma-Produktionsanlage mit Glasfassade und Industrieanlagen im Tageslicht
Indivior PLC mit ISIN GB00BYZ0C031 betreibt moderne Pharma-Produktionsanlage für innovative Suchtmedizin-Präparate weltweit an Patienten, Illustration mit AI erstellt.

Indivior stock closed at USD 35.91 on Nasdaq on September 23, 2026, down 0.77 percent. The Nasdaq Composite fell 1.13 percent to 26,936.04 points in the same session, a decline of 0.36 percentage points more than Indivior.

September 23, 2026 in numbers

Indivior Pharmaceuticals, Inc. (ISIN GB00BYZ0C031, Nasdaq: INDV) finished 15.9 percent below its 52-week high of USD 42.81 and USD 13.46 above its 52-week low of USD 22.55 on September 23, 2026. MarketScreener data recorded the Nasdaq close at USD 35.91 and a five-day gain of 4.54 percent.

As AD HOC NEWS reported on September 23, 2026, the company had declared a USD 8.13 special dividend linked to the planned merger with Supernus Pharmaceuticals. The distribution depends on completion of the transaction, with October 30, 2026 set as the record date and November 6, 2026 as the scheduled payment date.

Merger-linked dividend ahead

The October 30, 2026 record date is the next dated corporate event identified for Indivior shareholders. The USD 8.13 distribution remains conditional on the merger closing, according to AD HOC NEWS.

Disclaimer...

en | GB00BYZ0C031 | INDIVIOR | boerse | 70172861 | bgmi